氯吡格雷抵抗与卒中防治

[11] Lack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial[J] . Jacqueline Saw,Danielle M. Brennan,Steven R. Steinhubl,Deepak L. Bhatt,Koon-Hou Mak,Keith Fox,Eric J. Topol.Journal of the American College of Cardiology . 2007 (4)

[12] Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently .2 Farid NA,Payne CD,Small DS,et al. Clin Pharmacol Ther . 2007

[13] Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene, P2Y12, and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery Disease[J] . Sophie Ziegler,Martin Schillinger,Marion Funk,Katharina Felber,Markus Exner,Wolfgang Mlekusch,Schila Sabeti,Jasmin Amighi,Erich Minar,Martin Brunner,Markus Müller,Christine Mannhalter.Stroke . 2005 (7)

[14] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)[J] . The Lancet . 1996 (9038)

[11] Lack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial[J] . Jacqueline Saw,Danielle M. Brennan,Steven R. Steinhubl,Deepak L. Bhatt,Koon-Hou Mak,Keith Fox,Eric J. Topol.Journal of the American College of Cardiology . 2007 (4)

[12] Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently .2 Farid NA,Payne CD,Small DS,et al. Clin Pharmacol Ther . 2007

[13] Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene, P2Y12, and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery Disease[J] . Sophie Ziegler,Martin Schillinger,Marion Funk,Katharina Felber,Markus Exner,Wolfgang Mlekusch,Schila Sabeti,Jasmin Amighi,Erich Minar,Martin Brunner,Markus Müller,Christine Mannhalter.Stroke . 2005 (7)

[14] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)[J] . The Lancet . 1996 (9038)